Navigation Links
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
Date:2/19/2009

arter and full-year 2008 results. To access the live conference call, U.S. and Canadian participants may dial 866-730-5766; international participants may dial 857-350-1590. The access code for the live call is 52070700. To access the 24-hour audio replay, U.S. and Canadian participants may dial 888-286-8010; international participants may dial 617-801-6888. The access code for the call is 11605791. This conference call will also be webcast live and archived on ISTA's website for 30 days at http://www.istavision.com.

ABOUT ISTA PHARMACEUTICALS

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $4.7 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. Without limiting the foregoing, but by way of example, statements contained in this press release to the FDA's timely review and approval of Bepreve, ISTA's beliefs about the commercial success of Bepreve, the completion of a clinical study in support of T-Pred, the submission of supplement for T-Pred's NDA filing, the intention to select product or products to advance into Phase III trials in 2010, 2009 financial guidance and ISTA's goals of becoming operating income breakeven in 2009, and becoming the leading niche ophthalmic pharmaceutical compa
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... says the human brain operates much the same whether ... provide a better understanding of schizophrenia, bipolar disorder and ... 13.6 million Americans. , In newly published research in ... professor at the Center for Molecular and Behavioral Neuroscience, ... at rest is basically the same as that of ...
(Date:7/10/2014)... localized prostate cancer were more likely to be ... effective treatments and survived for shorter times than ... UCLA study has found. , The negative outcomes ... as bias against the mentally ill, depression,s impact ... of investment in his general health and disinterest ...
(Date:7/10/2014)... cakes that are just as tempting as full-fat ... to fresh insights into how proteins can replace ... , Funded by the Engineering and Physical Sciences ... and the University of Edinburgh has produced modified ... therefore closely mimic the behaviour of fats during ...
(Date:7/10/2014)... 10, 2014) Men who experience hot flashes are ... find relief from their silent suffering if they ... findings from a Baylor University case study., After seven ... had uncontrolled hot flashes following prostate cancer surgery showed ... also an impressive improvement in sleep quality, according to ...
(Date:7/9/2014)... The World Health Organization recommends that youth participate in ... physical activity (MVPA) each day. Studies have shown ... hours. Therefore, it stands to reason that increasing ... In a new study scheduled for publication in The ... spent outdoors after school was positively associated with MVPA. ...
Breaking Medicine News(10 mins):Health News:Working to loosen the grip of severe mental illness 2Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Go play outside! Outdoor time promotes physical activity in youth 2
... are cutting their transportation costs and reducing delivery times, as a ... customs processes. , ... Jericho, NY (Vocus) May 29, ... cutting their transportation costs and reducing delivery times, as a result ...
... Clinicians, researchers and scientists from around the world ... (DDW ), the largest and most prestigious gastroenterology ... the McCormick Place Convention Center, Chicago, IL. DDW is ... Institute, the largest and oldest GI society in the ...
... ProperSAN FRANCISCO, May 28 The following is a statement ... is a complete vindication for Blue Shield of California. ... It means that our underwriting procedures were fair and ... faith. There was no post-claims underwriting. The evidence ...
... to announce the introduction of the new Multi-Gas Plus ... These cartridges are unique because they do not ... can be used to work in environments up to ... OSHA guidelines are followed (service life graphs are available). ...
... researchers report that a combination of trastuzumab and neratinib ... receptor (ErbB2) appears active in women with HER2-positive metastatic ... therapies. More than one-quarter of the women in ... the combination therapy. , "I think this is ...
... could be targets for treatments, researchers say , , THURSDAY, May ... in the parts of their brains that monitor behaviors and ... vulnerable to addiction to the drug, a new research shows. ... in these regions of the brain when cocaine users were ...
Cached Medicine News:Health News:Purolator USA Offers Canadian Customs Expertise for Medical Device Exports 2Health News:AGA Institute presents cutting-edge research during DDW 2Health News:AGA Institute presents cutting-edge research during DDW 3Health News:AGA Institute presents cutting-edge research during DDW 4Health News:Draeger Announces New Multi-Gas Plus Cartridge 2Health News:Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer 2Health News:Brain Scans Show Differences in Cocaine Addicts 2
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
(Date:1/14/2014)... 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio ... acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... of the acquisition were not disclosed. Progressive ... a wide range of sleep, mobility, and respiratory products to ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Mumps IgG Enzyme- linked Immunosorbent Assay (ELISA) ... determination of IgG antibody to Mumps virus ... be used for the determination of immune ... be used to demonstrate seroconversion or a ...
The DSL-05-10-MUG Mumps IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgG-class antibodies to Mumps Virus in human serum. This assay is intended for in...
With BareWire technology, the wire crosses the lesion first, independent of the filter and delivery catheter. All other actions, including filter placement and retrieval, balloon dilatations, and ste...
... Ultra Laboratory has been uniquely designed ... single facility to integrated networks spanning ... to management reporting and accounts receivable, ... precise laboratory management. All system modules ...
Medicine Products: